stearic acid
Animal productexperimental
Zinc stearate is a mild antiseptic and astringent, and it has been used as a local soothing application for inflammatory and irritating skin diseases. Zinc stearate is primarily used in pharmacuetical formulations as a lubricant in tablet and capsule manufacture at concentrations up to 1.5% w/w. It is a protective agent used in powders and ointments in the treatment of eczema, acne, and other skin diseases. GRAS - Zinc stearate complies with FDA Standard CFR 21 sections 177.2600, 182.8994 and 178.2010. — NCATS
Clinical trial activity
6 trials · 15 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
1
Earliest trial started Aug 1, 2006 (NCT00343161)
Timeline
Indications
Approved for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Loading structure…
SMILES
[Zn++].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O- Mol. weight
- 632.348 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaStearic acid ↗
- NCATSH92E6QA4FV ↗
- ChEMBLCHEMBL46403 ↗
- NCATS4ELV7Z65AP ↗
Also known as
- 1-heptadecanecarboxylic acid
- 1-heptadecanecarboxylic acid
- aluminum monostearate
- aluminum tristearate
- ammonium stearate
- calcium stearate
- cetylacetic acid
- cetylacetic acid
- fatty acids c16-18
- magnesium stearate
- magnesium stearate
- magnesium stearate
- magnesium stearate
- n-octadecanoic acidd
- n-octadecanoic acidd
- octadecanoic acid
- octadecanoic acid
- octadecanoic acid
- octadecanoic acid
- octadecansaeure
- octadecansaeure
- octadecoic acid
- octadecoic acid
- ola
- ola
- sodium stearate
- sodium stearate
- sodium stearate
- stearate
- stearate
- stearic acid
- stearic acid
- stearic acid
- stearic acid
- stearic acid
- stearic acid
- stearic acid
- stearic acid
- stearin
- stearin
- stearinsaeure
- stearinsaeure
- zinc stearate
- zinc stearate
- zinc stearate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03746145 | N/A | Nov 15, 2018 | European Space Agency, Maastricht University, University of Lyon, University of Tuebingen |
| NCT02683408 | N/A | Feb 1, 2016 | Primus Pharmaceuticals |
| NCT01265953 | N/A | Jul 1, 2011 | Department of Veteran Affairs, National Cancer Institute (NCI), Oregon Health and Science University, Oregon State University |
| NCT00966225 | Phase 1 | Sep 1, 2009 | Afexa Life Sciences, Inc., University of Alberta |
| NCT00667589 | Phase 2 | Jun 1, 2008 | Bayer, Northwestern University |
| NCT00343161 | Phase 4 | Aug 1, 2006 | AstraZeneca, Evan. Jung-Stilling-Krankenhaus, Siegen, Germany |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Afexa Life Sciences, Inc. | For profit | 1 | 1 | 1 | 2009 |
| AstraZeneca | For profit | 1 | 1 | 1 | 2006 |
| Bayer | For profit | 1 | 0 | 1 | 2008 |
| Department of Veteran Affairs | Government | 1 | 1 | 1 | 2011 |
| European Space Agency | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Evan. Jung-Stilling-Krankenhaus, Siegen, Germany | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Maastricht University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2011 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Oregon Health and Science University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Oregon State University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Primus Pharmaceuticals | For profit | 1 | 1 | 1 | 2016 |
| University of Alberta | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Lyon | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Tuebingen | Academic/Hospital | 1 | 1 | 1 | 2018 |
15 organizations
Page 1 / 1